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Abstract In recent years, phosphodiesterase (PDE) inhibitors
have been frequently tested for the treatment of experimental
inflammatory and immune disorders. It is suggested that anti-
inflammatory properties of PDE inhibitors are related to their
ability to increase cAMP levels. The aim of this study was to
verify the hypothesis that cAMP may be a useful marker of
pharmacological response following administration of non-
selective PDE inhibitors (pentoxifylline and (±)-lisofylline)
to endotoxemic rats. Male Wistar rats were administered
LPS (1 mg kg−1, i.v.) simultaneously with either compound
given at two doses (40 and 80 mg kg−1, i.v.). Levels of cAMP
and both compounds in animal plasma were measured by the
v a l i d a t e d HPLC me t h o d s . P h a rm a c o k i n e t i c -
pharmacodynamic analysis was performed using basic and
modified indirect response (IDR) models II in Phoenix
WinNonlin. The results of this study indicate that, in contrast
to pentoxifylline, (±)-lisofylline demonstrates a non-linear
pharmacokinetics in rats with endotoxemia. In vitro study
using human recombinant PDE4B and PDE7A revealed the
occurrence of additive interaction between studied com-
pounds. Moreover, (±)-lisofylline is a more potent inhibitor
of PDEs compared to pentoxifylline, as evidenced by lower
IC50 values. Following administration of both compounds,
levels of cAMP in rat plasma increased in a dose-dependent
manner. The modified IDR model II better described cAMP
levels over time profiles. The validity of the proposed marker
was confirmed by measuring plasma TNF-α levels in the
studied animals. In conclusion, cAMP may be used in future
preclinical and clinical studies of some PDE inhibitors to eval-
uate the drug concentration–effect relationship.
Keywords cAMP . PK/PDmodelling . PDE inhibitors .
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Introduction
In recent years, phosphodiesterase (PDE) inhibitors have been
frequently tested as a potential treatment in sepsis and some
autoimmune disorders (Harada et al. 1989; Yang et al. 2005;
González-García et al. 2013). Especially, selective PDE4,
PDE7, or dual PDE4/7 inhibitors are widely studied as immu-
nomodulatory agents (Jankowska et al. 2017). Progression of
sepsis and autoimmune diseases depends on various factors,
but in both cases, the balance between T helper 1 (Th1) and T
helper 2 (Th2) lymphocytes has been indicated as the most
important one (Ferguson et al. 1999; Kunz and Ibrahim 2009).
Th1 lymphocytes produce pro-inflammatory cytokines such
as interferon-γ (INF-γ), interleukin-2 (IL-2) or tumour necro-
sis factor α (TNF-α), while Th2 lymphocytes release anti-
inflammatory cytokines, such as IL-4 and IL-5. Depending
on which cytokines predominate in plasma and target tissues,
progression or remission of the disease is observed (Selmi
2011; Noack and Miossec 2014; László et al. 2015). The cur-
rent treatment of sepsis and autoimmune diseases is not al-
ways efficient and often associated with severe side effects;
therefore, a search for new anti-inflammatory drugs is needed
in order to improve the therapeutic outcome in these diseases.
One of the most important steps in research and develop-
ment of new drugs is to find a suitable marker of
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pharmacological response. In experimental animal models of
immune disorders, cytokines such as interleukins (e.g. IL-6,
IL-10) and TNF-α or nitric oxide (NO) are usually used for
this purpose (Gozzi et al. 1999; Chakraborty et al. 2005;
Wyska 2010a; Lon et al. 2012). However, these biomarkers
have some limitations. First of all, their levels measured in
different species and in different individuals of the same spe-
cies differ significantly. Moreover, the increase in their con-
centrations is observed with some delay relative to the stimu-
lus (Lon et al. 2012). For these reasons, there is a need to
search for new biomarkers that are closely correlated with
the observed pharmacological effect in a dose-dependent
manner.
PDEs are responsible for 3 ′,5 ′-cyclic adenosine
monophosphate (cAMP) and 3′,5 ′-cyclic guanosine
monophosphate (cGMP) degradation; thus, the main mecha-
nism of action of PDE inhibitors is related to an increase in
levels of these nucleotides. Some PDE families are cGMP-
specific (PDE5, 6 and 9), some hydrolyse both cAMP and
cGMP (PDE1, 2, 3, 10 and 11) and others are cAMP-
specific (PDE4, 7 and 8). Due to ubiquitous expression of
PDE4 in mammalian organisms, this enzyme is primarily re-
sponsible for the cAMP degradation in the human body
(Houslay et al. 2005; Francis et al. 2011). The clinical impact
of changes in cAMP levels remains not entirely clarified, but
nevertheless, it has been shown that an increase in cAMP
amounts has an immune-weakening potential. On the other
h a n d , t h e r e d u c t i o n o f cAMP l e v e l s h a s a n
immunostimulatory effect (Raker et al. 2016).
Pentoxifylline (PTX) and lisofylline (LSF) are non-
selective PDE inhibitors that undergo metabolic interconver-
sion (Wyska et al. 2006). Thus, irrespective of which one is
administered, both compounds are present in blood. For many
years, they have beenwidely used in animal studies on inflam-
mation and autoimmune disorders (Rice et al. 1994; Bright
et al. 1998; Yang et al. 2002, 2003; Wyska 2010a). PTX is a
drug commonly used in the treatment of intermittent claudi-
cation. Moreover, it has been tested clinically in the treatment
of diseases, such as sepsis or pulmonary sarcoidosis in
humans (NCT02163174, NCT00001877). R-(-)-LSF is an en-
antiomer of PTX metabolite M1 recently investigated as a
potential treatment of autoimmune diabetes (NCT01603121).
It is well known that PDE inhibitors exert their anti-
inflammatory activity, at least in part, by increasing concen-
trations of cAMP. Therefore, it seems that this nucleotide may
serve as a marker of drug response in experimental models of
inflammatory disorders. To confirm this assumption, we eval-
uated the influence of two non-selective PDE inhibitors: PTX
and (±)-LSF on cAMP levels in plasma of rats with lipopoly-
saccharide (LPS)-induced endotoxemia. Based on these data,
two pharmacokinetic/pharmacodynamic (PK/PD) models
were developed to describe the relationship between plasma
concentrations of both compounds and their active
metabolites and pharmacological response. The potencies of
PTX and both enantiomers of LSF as inhibitors of human
recombinant PDE4B (hrPDE4B) and PDE7A (hrPDE7A)
were preliminarily assessed using an in vitro assay. To select
an appropriate PK/PD model, the nature of interaction be-
tween PTX and R-(-)-LSF or PTX and (±)-LSF was evaluated
in vitro using human recombinant PDE4B enzyme by the
combination index (CI) analysis. The validity of cAMP as a
biomarker was verified by measuring TNF-α levels in plasma
of endotoxemic rats treated with the studied compounds.
Materials and methods
Reagents
cAMP sodium salt, PTX (1-(5-oxohexyl)-3,7-dimethylpurine-
2,6-dione), dimethyl sulfoxide (DMSO), LPS (Escherichia
coli 055:B5) and 50% 2-chloroacetaldehyde water solution
were purchased from Sigma-Aldrich (Germany).
Temazepam (7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-
benzodiazepin-2-one) was a gift from Polfa (Poland). IBMX
(1-methyl-3-(2-methylpropyl)-7H–purine-2,6-dione) was pur-
chased from Santa Cruz Biotechnology (USA). (±)-LSF ((±)-
1-(5-hydroxyhexyl)-3,7-dimethylpurine-2,6-dione) was ob-
tained from the Department of Organic Chemistry, Faculty
of Chemistry, Jagiellonian University (Cracow, Poland).
R-(-)-LSF and S-(+)-LSF were isolated by chromatographic
separation of racemate using a chiral semi-preparative
Chiralpak AD column (Daicel Corp., Japan). Other chemicals
were of high-performance liquid chromatography or analyti-
cal reagent grade and were purchased fromMerck (Germany).
In vitro PDE assay
The PDE inhibitory activity of PTX, R-(-)-LSF and S-(+)-LSF
was evaluated using the PDE-Glo Phosphodiesterase Assay
according to the manufacturer’s instruction (Promega
Corporation, Madison, WI, USA). Briefly, 1,5 μl of 1×
PDE-Glo reaction buffer containing 10 mU of purified
hrPDE4B or hrPDE7A (SignalChem, Richmond, Canada)
was pipetted into 384-well plate wells (Thermo Scientific,
USA). The tested compounds were dissolved in DMSO, and
a serial dilution of the inhibitors was performed using 1×
PDE-Glo reaction buffer. Then, 1 μL of diluted inhibitors
and 2.5 μL of cAMP solution were added to each well.
After 10 min of incubation in 30 °C, 2.5 μL of PDE-Glo™
Termination Buffer and 2.5 μL of PDE-Glo™ Detection
Solution were added and the plate was incubated for 20 min
at room temperature. Finally, 10 μL of Kinase-Glo® Reagent
was pipetted to each well and after 10 min of incubation, the
luminescence was measured using a microplate luminometer
(POLARstar Omega, BMG LABTECH, Ortenberg,
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Germany). All data points are the average of two
determinations.
Combination index analysis
CompuSyn (ComboSyn, Inc., Paramus, NJ, USA) computer
program was used in the calculation of the CI of non-constant
ratio combinations of PTX with R-(-)-LSF or PTX with (±)-
LSF as hrPDE4B inhibitors. The CI was evaluated based on
the Combination Index-Isobologram Theorem (Chou 2006).
CI values = 1, >1 and <1 indicate an additive effect, antago-
nism and synergism, respectively. However, values between
0.9 and 1.1 are considered as nearly additive. To this end, four
concentrations of each drug producing between 25 and 75%
of the maximal inhibitory potency (data obtained from the
single compound study) were chosen. In the next step, four
concentrations of PTX and R-(-)-LSF or PTX and (±)-LSF
were mixed with each other to produce 32 combinations of
investigated compounds (16 combinations for each pair of
compounds). The inhibitory potencies of all combinations
were measured using the described above PDE-Glo
Phosphodiesterase Assay.
Animals
Male Wistar rats weighting 250–300 g were housed in condi-
tions of the constant temperature with a 12:12 h light–dark
cycle with free access to food and water. The animals were
implanted with catheters (SAI Infusion Technologies, USA)
in the jugular vein under ketamine/xylazine anaesthesia 2 days
prior to the experiment. Before drug administration, the rats
were fasted overnight with free access to water. All animal
procedures were approved by the First Local Ethical
Committee on Animal Testing at the Jagiellonian University.
All applicable international, national and/or institutional
guidelines for the care and use of animals were followed.
In vivo experimental design
All compounds were directly dissolved in 0.9% sterile saline
and used within 1 day of preparation. The animals were divid-
ed into five groups (n = 3–4). The control group received LPS
alone at a dose of 1 mg kg−1, whereas the other four groups
received one of the tested compounds (PTX or (±)-LSF) at a
dose of 40 or 80 mg kg−1 simultaneously with LPS given at a
dose of 1 mg kg−1. All injections (1 mL kg−1) were given to
the tail vein of the rat under isoflurane anaesthesia. Blood
samples were collected from the jugular vein catheter into
snap-cap propylene tubes containing heparin at 0, 15, 30,
60, 75 and 90 min following administration of PTX and at
0, 15, 30, 60, 90 and 120 min following (±)-LSF dosing.
Subsequently, samples were kept on ice and centrifuged for
10 min at 3000×g at 4 °C (EBA 12 R, Hettich, Germany). The
individual plasma samples were harvested and stored at
−80 °C until analysis.
Analytical methods
In order to isolate studied compounds and their metabolites
from plasma, to 100 μL of plasma (or plasma spiked with
methanol standard solution of PTX or (±)-LSF), 10 μL of
temazepam (internal standard) solution in methanol and
20 μL of 1 M hydrochloric acid water solution were added.
Then, the samples were extracted with 3 mL of dichlorometh-
ane for 20 min on a shaker (VXR Vibrax, IKA, Germany).
Subsequently, all tubes were centrifuged (2000×g, 15 min)
and organic layers were transferred to new glass tubes and
evaporated under gentle stream of nitrogen at 37 °C. Dry
residues were dissolved in 100 μL of mobile phase and placed
in the autosampler vials. The volume of injection was set to
50 μL. The HPLC system (LaChrom Elite, Merck-Hitachi,
Darmstadt, Germany) consisted of an L-2130 pump, an L-
2200 autosampler, an L-2450 diode array detector and an L-
2350 column oven. EZChrome Elite v. 3.2 (Merck-Hitachi)
software was used for data acquisition. The analysis was per-
formedonaLiChrospher 100RP-18 column (250mm×4mm)
with a particle size of 5 μm protected with a LiChroCART
(4 mm × 4mm) guard column (Merck, Germany). The mobile
phase consisted of dioxan, acetonitrile and aqueous solution of
acetic acid (pH = 3.0) mixed at the ratio of 6.5:6.5:87 (v/v/v),
respectively, and pumped at a flow rate of 1.2 mL min−1.
Analytical wavelength was set to 275 nm and temperature of
separation was 35 °C. In these conditions, the retention times
were found to be 15.5 min for temazepam, 17.5 min for PTX
and 21 min for (±)-LSF.
The levels of cAMP in rat plasma were measured using the
same HPLC system and a fluorescence detector (model FL-
2485). The analysis was performed after incubation of plasma
with 2-chloroacetaldehyde as a derivatization reagent in ele-
vated temperature to form the fluorescing derivative—1,N6-
etheno-cAMP. To 100 μL of plasma (or plasma spiked with
water standard solution of cAMP), 15 μL of 2 M 2-
chloroacetaldehyde solution and 50μL of 0.5M acetate buffer
(pH = 4.5) were added to a snap-cap tubes. Samples were then
vortex-mixed (Reax top, Heidolph, Germany) for 20 s and
incubated at 80 °C for 20 min. Thereafter, the reaction mixture
was cooled on ice, the samples were centrifuged (3000×g,
10 min) and 100 μL of supernatants was placed in the
autosampler vials. The volume of injection was 50 μL. The
separation was performed at isocratic conditions at 35 °C
using the mobile phase composed of 20 mM citric-
phosphate buffer (pH = 3.2) and methanol mixed at the ratio
of 91:9 (v/v) and pumped at a flow rate of 1.3 mL min−1. The
excitation and emission wavelengths were set to 280 and
420 nm, respectively. In these conditions, the retention time
of 1,N6-etheno-cAMP was 6 min.
Naunyn-Schmiedeberg's Arch Pharmacol (2017) 390:1047–1059 1049
No interfering peaks were observed at the retention times
of the analytes and the internal standard. The calibration
curves for (±)-LSF and PTX constructed by plotting the peak
area ratios of the analytes to the internal standard versus cor-
responding concentrations of analytes were linear in a range of
0.1 to 125 μg mL−1. For cAMP, the calibration curve was
obtained by plotting the peak areas of cAMP versus corre-
sponding concentrations of this nucleotide and it was linear
in a range of 10 to 500 pmolmL−1. All values for accuracy and
precision were within the recommended limits (EMA 2011).
Plasma TNF-α levels were measured by rat TNF-α
Quantikine ELISA kit (R&D Systems, Minneapolis, MN,
USA) according to the manufacturer’s protocol. The limit of
quantification was 12.5 pg mL−1.
Pharmacokinetics
Two independent PK models were developed for each parent
drug, namely PTX or (±)-LSF, and their active metabolites fol-
lowing intravenous (i.v.) route of administration. To this end,
one- or two-compartment pharmacokinetic models with linear
orMichaelis–Menten type saturable elimination from the central
compartment were tested. Both dose levels in each case were
simultaneously fitted to obtain a single set of parameters. The
final pharmacokinetic models for PTX and (±)-LSF were select-
ed on the basis of visual inspection of the fitting, examination of
residuals, parameter precision, Akaike Information Criteria
(AIC), Bayesian Information Criteria (BIC) and analysis of the
correlation matrix. Pharmacokinetic analysis was performed
using Phoenix WinNonlin v. 6.3 (Pharsight Corp, Certara, St.
Louis, MO, USA).
Pharmacodynamics
The indirect response (IDR) model II was employed to de-
scribe pharmacodynamics of PTX and (±)-LSF as non-
selective PDE inhibitors (Fig. 1). This selection was based
on the fact that both compounds inhibit degradation of
cAMP used in this study as a marker of drug response.
Changes in plasma cAMP concentrations (CcAMP) over
time following each compound administration may be de-
scribed by the following equation:
dCcAMP
dt
¼ kin−kout⋅I tð Þ⋅CcAMP ð1Þ
where kin is zero-order cAMP production rate constant and
kout is the first-order cAMP elimination rate constant. In the
absence of drug, the response stays at the baseline value (R0):
R0 ¼ kinkout ð2Þ
Thus, kin can be calculated as R0 kout, where R0 is the mean
cAMP concentration measured before drug administration.
The joint effect of PTX and (±)-LSF as parent drugs and
metabolites was modelled using two approaches.
The first approach (Fig. 1a) was based on the as-
sumption that both compounds, PTX and (±)-LSF, act
with similar potencies; thus, inhibitory function may be
described by the following equation:
I tð Þ ¼ 1− Imax⋅Cp
γ
IC50γ þ Cpγ ð3Þ
where Cp is a sum of PTX and (±)-LSF plasma con-
centrations, Imax is the maximum ability of both com-
pounds to inhibit kout, IC50 is plasma concentration of
the combination of parent compound and metabolite at
which inhibition is half-maximal, and γ is the Hill
coefficient.
The second approach assumes that both compounds under in-
vestigation act with different potencies. Based on the results of the
in vitro study, an additive interaction model was used (Eq. 4):
I tð Þ ¼ 1− Imax;PTX ⋅CPTX
γPTX
IC50;PTXγPTX þ CPTX γPTX
 
⋅ 1−
Imax;LSF⋅CLSFγLSF
IC50;LSFγLSF þ CLSFγLSF
 
ð4Þ
where Imax,PTX and Imax,LSF, are the maximum ability
of PTX and (±)-LSF, respectively, to inhibit kout;
IC50,PTX and IC50,LSF are the concentrations of PTX
and (±)-LSF producing 50% of the maximum inhibition;
CPTX and CLSF are plasma concentrations of PTX and
(±)-LSF and γPTX and γLSF are the Hill coefficients.
Imax and γ in Eqs. (3) and (4) were fixed to 1 during
fitting procedure. To obtain a single set of pharmacody-
namic parameters for each model, cAMP plasma con-
centrations following administration of PTX or (±)-LSF
at both dose levels (40 or 80 mg kg−1) were fitted
simultaneously.
Statistical analysis
The peak cAMP and TNF-α plasma levels following
administration of LPS alone or LPS simultaneously
with both doses of each compound were compared
using a one-way ANOVA and Tukey’s HSD post hoc
test. The normality of data distribution was checked by
Shapiro–Wilk test. The relationship between decimal
logarithms of peak cAMP and TNF-α plasma concen-
trations was verified by least squares linear regression
analysis. All statistical analyses were performed using
Statistica v. 12 (StatSoft Inc., USA). The significance
level p was set at 0.05.
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Results
PDE inhibitory activity and CI analysis
As presented in Fig. 2a, b, and in Table 1, both enantiomers of
(±)-LSF inhibited hrPDE4B in the in vitro assay with similar
potencies. PTX in the same test acted slightly weaker. R-(-)-
LSF and S-(+)-LSF act also as weak inhibitors of hrPDE7A,
whereas PTX as an inhibitor of this enzyme was ineffective.
IBMX, a non-selective PDE inhibitor used as a reference com-
pound in this study, reached PDE7A IC50 value about 3 and 4
times lower than those of R-(-)-LSF and S-(+)-LSF, respec-
tively.Moreover, this compound acted two times stronger than
PTX and similarly to both enantiomers of LSF as a hrPDE4B
inhibitor.
CI values of each compound combination were plotted on
CI plots, where the effect value (x axis) is a summary % of
hrPDE4B inhibition of each combination (Fig. 2c, d). CI
values obtained for seven of the 16 combinations of PTX
and R-(-)-LSF (Fig. 2c) and for 11 of 16 combinations of
PTX and (±)-LSF (Fig. 2d) were in the range of 0.9–1.1,
indicating the existence of simple additive interaction. CI cal-
culated for other combinations slightly exceeded the range of
0.9–1.1 indicating the presence of weak antagonism or syner-
gism. However, the mean CI value obtained for all combina-
tions of PTX and R-(-)-LSF was 1.02 (±0.12), and for PTX
and (±)-LSF combinations, it was 0.95 (±0.14).
Pharmacokinetics
Pharmacokinetic analysis revealed that a one-compartment
model with linear elimination from the central compartment
(Fig. 3a) best described PTX and (±)-LSF (as metabolite) con-
centration versus time profiles after i.v. administration of PTX
to rats. In turn, a one-compartment model with Michaelis-
Menten type elimination from the central compartment (Fig.
3b) was most appropriate to fit the plasma concentration ver-
sus time data of (±)-LSF and PTX (as metabolite) after (±)-
LSF i.v. administration to rats. In both models, a mutual inter-
conversion of the parent compounds and their metabolites was
taken into account.
As presented in Fig. 4, the proposed models very well
captured the concentration versus time data of both parent
compounds and their respective metabolites.
The estimates of pharmacokinetic parameters are listed in
Table 2.
Pharmacodynamics
The administration of investigated compounds to rats caused
an inhibition of PDEs and a subsequent increase in cAMP
levels in rat plasma in a dose-dependent manner with the peak
concentration attained between 30 and 60min post-(±)-LSF or
PTX dosing. The first tested PK/PD model (Fig. 1a) is a basic
IDR model II, where Cp is a sum of the parent drug and its
active metabolite concentrations. The second tested model
(Fig. 1b) is an additive interaction IDR model II, where the
occurrence of a simple additive interaction between studied
compounds is assumed. Both models describing endogenous
cAMP levels consisted of one zero-order input (kin) and one
first-order cAMP elimination rate constant (kout).
The appropriateness of these models was evaluated on the
basis of goodness-of-fit criteria. The second model (Fig. 1b)
was found to better characterize changes in cAMP levels over
time in the presence of both PDE inhibitors. An improvement
in the fitting was observed, when comparing to the first tested
model, as can be determined by visual inspection of the fitting
(Fig. 5). Moreover, the AIC and BIC values for the interaction
model (229.2 and 232.7, respectively) were lower in compar-
ison with the values estimated for basic IDR model II (232.9
and 235.3, respectively). Pharmacodynamic parameters esti-
mated using both models are listed in Table 3.
A slightly lower value of IC50 estimated using the interac-
tion model for (±)-LSF suggests that this compound may be
more potent than PTX as an inhibitor of PDEs in vivo.
To verify whether cAMP levels increased in a dose-
dependent manner, the peak cAMP plasma concentrations
following administration of LPS only and LPS simultaneously
with two different doses of either compound were compared
statistically (Fig. 6a, b).
Surprisingly, (±)-LSF administered at a dose of 40 mg kg−1
did not increase (p > 0.05) the peak cAMP level in comparison
with the group receiving LPS only. The lack of statistical
difference in this case may be partially explained by a small
sample size. In contrast, the peak TNF-α levels following LPS
administration were significantly lower (p < 0.05) in the pres-
ence of both compounds administered at two dose levels (Fig.
6c, d). The results of linear regression analysis indicate the
Fig. 1 Schematic representations
of the proposed
pharmacodynamic models
following intravenous
administration of PTX or (±)-LSF
to endotoxemic rats: the simple
IDR model II (a) and the additive
interaction IDR model II (b)
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occurrence of correlation between the decimal logarithms of
peak cAMP and TNF-α plasma levels (Fig. 7).
Each data point was plotted using TNF-α and cAMP con-
centrations obtained from the same rat. The correlation be-
tween plasma levels of cAMP and those of a commonly used
biomarker of inflammation—TNF-α confirms the validity of
cAMP as a marker of pharmacological response following
administration of non-selective PDE inhibitors.
Discussion
PK/PD modelling is widely used in the pharmaceutical indus-
try worldwide not only for quantitative effect-time data anal-
ysis but also for predictions of pharmacological response over
time in new experimental conditions, such as different dose,
dosing schedule, new routes of administration or in the case of
decreased function of elimination organs. Properly selected
biomarker that reflects the clinical effect is the key to success
in the development of a new drug. Biomarker is defined as a
measure that characterizes, in a quantitativemanner, a process,
which is located on the path between drug administration and
effect (Danhof et al. 2005). A good biomarker should exhibit
Bconsistent characteristics with an acceptable sensitivity and
specificity representing a specific toxicity or therapeutic effect
of the drug, a specific physiological response to a treatment, a
pathological progression or a physiological factor^ (Bai et al.
2011). As shown in this study, cAMP measured in plasma
after administration of non-selective PDE inhibitors meets
these criteria.
Literature data indicate that in experimental models of in-
flammatory diseases, PK/PD models were built using TNF-α,
IFN-γ, IL-10 or NO as markers of pharmacological response
(Gozzi et al. 1999; Chakraborty et al. 2005; Wyska 2010a).
The major drawback of using cytokines as biomarkers to eval-
uate anti-inflammatory drug effects is that their concentrations
in blood are highly variable between different individuals of
the same species. The results presented in literature show a
large inter-study variation in the values of cytokine levels
(several times differences), despite similar experimental con-
ditions. For example, after intraperitoneal injection of LPS at
an identical dose to the same strain of mice, the reported levels
of TNF-α differed several times (Gozzi et al. 1999; Wyska
2010a). This diversity may be due to the methods of blood
sampling and further processing of the biological material
(e.g., time and temperature of centrifugation, use of
Fig. 2 Observed (symbols) vs.
predicted (lines) hrPDE4B (a) or
hrPDE7A (b) activity (%) in the
presence of the investigated
compounds at different
concentrations; CI plots of 16
combinations of PTX and R-(-)-
LSF (c) or PTX and (±)-LSF (d)
as hrPDE4B inhibitors
Table 1 IC50 values of studied inhibitors estimated by non-linear re-
gression using data obtained from in vitro study
Compound PDE4B IC50 (μM) PDE7A IC50 (μM)
R-(-)-LSF 49.1 266.1
S-(+)-LSF 52.5 328.2
PTX 91.3 >500.0
IBMX 46.6 77.7
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anticoagulants, sample storage conditions or the time allowed
for blood clotting). A similar effect has been found in studies
involving the CLP-induced model of sepsis (Otero-Antón
et al. 2001; Singleton et al. 2003). cAMP as a non-protein
biomarker seems to be less prone to these factors. As a result,
the values of endogenous concentrations of this nucleotide
observed in the present study are close to those found in the
literature (Gomaa et al. 2003; Itoh et al. 2004). Another dis-
advantage of using cytokines as markers of pharmacological
effect is that the increase in their levels is observed with a
delay relative to the stimulus, which may be somewhat
problematic in PK/PD modelling, as it requires using an addi-
tional tlag (lag time) parameter (Lon et al. 2012). cAMP is not
burdened with this disadvantage because the increase in its
levels begins immediately after administration of cAMP-
elevating compounds, and it attains the peak level between
30 and 60 min thereafter.
cAMP has been frequently measured in in vitro studies,
including those on pharmacodynamics of PDE inhibitors
(D’Alessandro et al. 2013; Huang et al. 2015; Massimi et al.
2017). Moreover, there are several examples of measuring its
concentrations in animal tissues (Kitazawa et al. 1999; Jin
Fig. 3 Schematic representations of the proposed pharmacokinetic
models of PTX (a) and (±)-LSF (b) following intravenous
administration of each compound to rats; CPTX and CLSF, plasma
concentrations of PTX and (±)-LSF; VPTX and VLSF, volumes of PTX
and (±)-LSF compartments, respectively; VPTXm and VLSFm, volumes of
PTX and (±)-LSF metabolite compartments, respectively; km12, first-
order conversion rate constant of parent compound into metabolite;
km21, first-order conversion rate constant of metabolite into parent com-
pound; ke, first-order rate constant for disappearance of parent compound;
fm, fraction of parent compound metabolized; kem, first-order elimination
rate constant of metabolite; Vmax, maximal elimination rate constant; Km,
drug concentration at which the elimination rate is half-maximal
Fig. 4 Mean (±SD) observed
(symbols) and model predicted
(lines) PTX and (±)-LSF plasma
concentrations after PTX (a) or
(±)-LSF (b) administration at two
doses (40 or 80 mg kg−1) to rats
(n = 3–4)
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et al. 2004; Park et al. 2016) or plasma (Cheng et al. 1997;
Tanahashi et al. 1999). However, the pharmacodynamic data
obtained in these studies have not been analysed quantitative-
ly. The only exception is the study of Jusko and coworkers,
where cAMP levels in liver following acute and chronic meth-
ylprednisolone administration in adrenalectomized rats were
modelled using the IDR model II (Jin et al. 2004). cAMP
plasma levels have been also monitored in humans. Baseline
levels of cAMP in plasma of healthy subjects obtained from
different studies vary from 13 to 25 pmol mL−1 (Nishikimi
et al. 1995; Amado et al. 1999; Cocks et al. 2000; Li and Liu
2013). Elevated levels of cAMP were observed in patients
with major blunt trauma (Cocks et al. 2000), heart failure
(Nishikimi et al. 1995), after thoracic epidural analgesia (Li
and Liu 2013), after heart surgery under cardiopulmonary by-
pass, which triggers a systemic inflammatory response
(Amado et al. 1999), as well as in patients treated with
antiplatelet drug—ticagrelor (Li et al. 2017). Furthermore,
melatonin (pineal hormone) administered orally significantly
augmented cAMP plasma levels in humans 1 h following its
administration (Zhdanova and Raz 1999). The extent of mean
cAMP level elevation in these conditions and treatments was
not higher than two times in comparison to that observed in
control groups. Following intravenous infusion of PTX at a
dose of 300mg in 1 h to healthy subjects, cAMP plasma levels
measured 1 h from the beginning of infusion were elevated by
approximately 50% when compared to the placebo group
(Kruuse et al. 2000). To our knowledge, there is a lack of
information in the literature about the influence of sepsis state
on cAMP levels in human plasma; thus, this issue needs fur-
ther research. Due to the potential use of PDE inhibitors in the
treatment of a wide range of inflammatory diseases, it would
be necessary to investigate the effect of these diseases on
cAMP levels in plasma before applying cAMP as a marker
Fig. 5 Mean (±SD) observed
(symbols) and predicted (lines)
based on the basic IDR model II
(a) and additive interaction IDR
model II (b) plasma cAMP
concentrations after PTX or (±)-
LSF administration at two doses
(40 or 80 mg kg−1) to rats (n = 3–
4)
Table 2 Estimated values of
pharmacokinetic parameters of
PTX or (±)-LSF as parent
compounds
(±)-LSF (parent drug) PTX (parent drug)
Parameter Final estimate (CV%) Parameter Final estimate (CV%)
VLSF (L kg
−1) 1.22 (3.44) VPTX (L kg
−1) 1.07 (1.24)
VPTXm (L kg
−1) 2.01 (9.48) VLSFm/fm (L kg
−1) 1.77 (15.23)
Vmax (mg min
−1 kg−1) 0.433 (56.85) ke (min
−1) 0.056 (3.04)
Km (mg L
−1) 6.02 (91.82) km21 (min
−1) 0.015 (9.89)
km12 (min
−1) 0.203 (12.74) kem (min
−1) 0.157 (15.34)
km21 (min
−1) 0.095 (12.87)
kem (min
−1) 0.116 (9.75)
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of pharmacological response in PK/PD modelling. Our own
unpublished data show that in cecal ligation and puncture
(CLP)-induced model of sepsis, which is probably the most
frequently used as it closely resembles the progression and
characteristics of human sepsis, cAMP serum concentrations
in mice were reduced at 24 and 72 h following CLP procedure
and were 26.4 (±3.5), 28.9 (±0.5), 18.0 (±0.4) and
9.3 pmol mL−1 (±0.5) in the control group and at 8, 24 and
72 h after CLP procedure, respectively. Therefore, when using
this model of sepsis and cAMP as a biomarker, the baseline
response should be described by a more complex equation.
It is well known that cAMP participates in multiple down-
stream pathways, but one of its most important actions is
activation of the cAMP-dependent protein kinase A (PKA) I
(Walsh et al. 1968). This nucleotide binds to the regulatory
subunits of PKA I, leading to its dissociation into the regula-
tory and catalytic subunits. Subsequently, catalytic subunits of
PKA I phosphorylate specific residues on multiple target pro-
teins initiating the appropriate signalling pathways (Walsh and
Van Patten 1994). cAMP-activated PKA I binds and phos-
phorylates cAMP-responsive transcription factors, such as
cAMP-response element binding protein (CREB) (Shaywitz
and Greenberg 1999), activating transcription factor-1 (ATF-
1) (Rehfuss et al. 1991), nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) (Houslay et al. 2005)
and nuclear receptors (Martin et al. 2009; Liu et al. 2009). This
pathway is responsible for the regulation of immune response
and the production of inflammatory cytokines (Jankowska
Fig. 6 Effects of different doses
of PTX and (±)-LSF on the peak
cAMP plasma concentrations
(±SD) (n = 4) (a, b) and on TNF-
α plasma concentrations (±SD)
(c, d) at 90 min following i.v. ad-
ministration of each compound
concomitantly with LPS (n = 4)
Table 3 Pharmacodynamic
parameters estimated using both
tested pharmacodynamic models
following intravenous
administration of PTX or (±)-LSF
to rats challenged with LPS
Basic indirect response model II Interaction indirect response model II
Parameter Final estimate (CV%) Final estimate (CV%)
kin (pmol mL
−1 min−1) 9.709 (NEa) 6.650 (NEa)
kout (min
−1) 0.511 (14.06) 0.350 (10.54)
IC50, PTX (mg L
−1) – 4.478 (22.24)
IC50, LSF (mg L
−1) – 3.428 (19.07)
IC50 (mg L
−1) 2.243 (9.28) –
aNot estimated
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et al. 2017). Moreover, elevated levels of cAMP cause down-
regulation of T cell proliferation and effector functions. The
mechanism of this activity is not entirely clarified, but there
are some indications that it may be associated with the induc-
ible cAMP early repressor (ICER) (Bodor et al. 1996).
Till today, two independent studies have shown that inhi-
bition of PDE4 isoform is responsible for the elevated levels
of cAMP in animal blood. Rolipram (a selective PDE4 inhib-
itor) but no cilostamide (a selective PDE3 inhibitor) elevated
plasma cAMP concentration in dogs in a dose-dependent
manner (Tanahashi et al. 1999). Similarly, CP-80,633 and
rolipram, selective PDE4 inhibitors administered at the same
dose of 10 mg kg−1 p.o., increased plasma cAMP concentra-
tions in mice. In the same study, selective inhibitors of PDE1
(vinpocetine), PDE2 (dipyridamole), PDE3 (SKF-94,120),
and PDE5 (zaprinast), given at a 10 times higher dose than
that of the PDE4 inhibitors, failed to alter cAMP levels signif-
icantly (p < 0.05) in these tests. Moreover, a non-selective
PDE inhibitor theophylline, when administered orally at a
dose of 100 mg kg−1 to mice, increased plasma levels of
cAMP up to 296.9 pmol mL−1 at 20 min post-dose (Cheng
et al. 1997), whereas after i.p. dose of 50 mg kg−1 to rats
with endotoxemia, it elevated concentrations of this nu-
cleotide to 228.22 pmol mL−1 0.5 h after drug admin-
istration (our own unpublished data). It is quite possible
that basophiles, mast cells, neutrophils, eosinophils,
monocytes and lymphocytes, which contain PDE4 and
PDE7 enzymes (Torphy and Undem 1991; Smith et al.
2003), are involved in the accumulation and efflux of
cAMP as a result of the treatment with non-selective as
well as PDE4 and PDE7-selective PDE inhibitors
(Cheng et al. 1997). Taken together, these data suggest
that plasma concentrations of cAMP elevated by PDE
inhibitors may be connected with an increased cAMP
export from PDE4-sensitive immune cells and PDE7
inhibition may enhance this effect.
In the in vitro study conducted using human recombinant
PDE4B and PDE7A, the main cAMP-hydrolysing enzymes,
the IC50 values of IBMX as a reference compound were sim-
ilar to those found in literature (Hatzelmann et al. 1995; Smith
et al. 2004). We noticed a higher PDE inhibitory potency of
(±)-LSF enantiomers in comparison to PTX. Moreover, both
R-(-)-LSF and S-(+)-LSF demonstrated comparable IC50
values as PDE4B and PDE7A inhibitors. Therefore, in the
pharmacodynamic models employed in this study, it was as-
sumed that both enantiomers of LSF exhibit the same PDE
inhibitory potency. Up to date, it has been believed that only
R-(-)-enantiomer of (±)-LSF exhibits pharmacological activity
(Nicklasson et al. 2002). For example, it has been demonstrat-
ed that R-(-)-LSF, unlike S-(+)-LSF, inhibited IL-12-induced
murine T helper 1 (Th1) differentiation in a dose-dependent
manner (Bright et al. 1998). In this paper, we demonstrated for
the first time that both enantiomers of (±)-LSF act with a
similar potency at least as PDE4B and PDE7A inhibitors.
Thus, the differences observed in previous studies may arise
from other mechanisms of anti-inflammatory activity of R-(-)-
LSF. It has been shown that this enantiomer may act through
multiple mechanisms, among which inhibition of STAT-4
(Yang et al. 2003) or phosphatidic acid generation (Bleich
et al. 1996) can be mentioned as examples. However, little is
known about properties of S-(+)-LSF, leaving a gap for further
research. As PTX and (±)-LSF undergo metabolic intercon-
version in blood (Nicklasson et al. 2002; Wyska et al. 2006)
and both compounds exert anti-inflammatory effects, we
made an attempt to assess the nature of possible interaction
that might occur. CI values calculated using CompuSyn soft-
ware for PTX and R-(-)-LSF as well as for PTX and (±)-LSF
oscillated around 1, indicating existence of additive (zero)
interaction between both investigated compounds. This obser-
vation was taken into account during pharmacodynamic mod-
el building and finally, the additive interactionmodel was used
in PK/PD analysis.
As mentioned above, PTX and R-(-)-LSF are prone to met-
abolic interconversion. The reduction of PTX to R-(-)-LSF is
mediated by an enzyme independent on cytochrome P450,
namely carbonyl reductase; on the other hand, the opposite
reaction is catalysed by CYP1A2 (Lee and Slattery 1997).
Moreover, PTX is metabolised to S-(+)-LSF. Thereby, after
administration of PTX or (±)-LSF to rats, all three com-
pounds, namely PTX and both enantiomers of (±)-LSF, occur
in blood. Therefore, our PKmodels have some limitations. As
we used a non-chiral method for determination of (±)-LSF
concentrations, the parameter values obtained for (±)-LSF in
fact relate to the combination of the two enantiomers co-
occurring in rat plasma. The results of the previous study
indicated that interconversion rates of PTX and R-(-)-LSF,
as well as PTX and S-(+)-LSF, are different and that this
process plays a minor role in the pharmacokinetics of both
compounds (Wyska et al. 2006). Despite the simplification
Fig. 7 Double logarithmic plot of TNF-α plasma peak levels as a func-
tion of cAMP plasma maximal concentrations in rats with endotoxemia
receiving LPS alone or simultaneously with PTX or (±)-LSF
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of pharmacokinetic models in this study, both pharmacokinet-
ic models very well captured changes in concentrations of the
tested compounds in rat plasma. The pharmacokinetic analy-
sis confirmed the results of previous research on mice indicat-
ing the presence of non-linear pharmacokinetics of R-(-)-LSF
administered alone or concomitantly with LPS (Wyska 2010a;
Wyska et al. 2015). Unlike PTX, this compound is metabo-
lized in mice principally by cytochrome P450 (Lee and
Slattery 1997; Wyska 2010b); thus, the saturation of metabo-
lism at higher doses may occur. Both PTX and (±)-LSF are
rapidly eliminated from the rat body, as demonstrated by the
fast decline of the terminal phase of the concentration versus
time profiles. The elimination half-life (t0.5) of PTX equalled
16.4 min, and it was two times longer than that observed in
mice (Wyska et al. 2007). In turn, the values of Km or Vmax of
(±)-LSF estimated in rats (Table 2) were somehow lower than
those obtained for R-(-)-LSF in mice (15.08 mg L−1 and
2.33 mg min−1 kg−1, respectively) (Wyska et al. 2007).
In this study, we used cAMP as a marker of pharmacolog-
ical response after administration of compounds that modulate
the level of this nucleotide and evaluated the in vivo potency
of the investigated compounds using PK/PD modelling. As
demonstrated in this paper, after administration of both PDE
inhibitors, cAMP levels changed in a dose-dependent manner.
The proposed PK/PDmodels are based on the assumption that
both compounds (PTX and (±)-LSF) cause a reduction in
degradation of cAMP by PDE (principally PDE4) inhibition.
The first tested PK/PDmodel, which is the basic IDRmodel II
(Fig. 1a) is simpler and can be successfully used in a situation
where only one compound, which exhibits pharmacological
activity, occurs in blood. The second model—the interaction
IDR model II (Fig. 1b)—reflects a more complex situation
when two active compounds are present in blood, and they
undergo additive interaction. Furthermore, each compound
has a different potency. This approach is based on the additive
drug–drug interaction model developed by Ariens et al.
(1957). The PK/PD analysis revealed that the second model
(Fig. 1b) better described changes of cAMP levels over time
following administration of studied compounds. It may be
justified by the fact that both parent compounds and their
active metabolites occur in rat blood, and they exhibit phar-
macological activity as PDE inhibitors. Basic assumptions of
this model are that both parent compounds and their respective
active metabolites exhibit additive (zero) interaction (as it can
be concluded from the results of CI analysis), and both enan-
tiomers of (±)-LSF have the same potency as PDE inhibitors
(based on the similar IC50 values obtained in the in vitro
study). As the investigated compounds at higher concentra-
tions fully inhibited activity of the enzymes in the in vitro test,
in both compared pharmacodynamic models, Imax value was
fixed to 1. The employed PK/PD models allowed for assess-
ment of the PDE inhibitory potency of tested compounds
in vivo. Based on the obtained results, it seems that (±)-LSF
is a slightly stronger inhibitor of PDEs in rats compared to
PTX, as demonstrated by approximately 20% lower IC50 val-
ue (Table 2). Also, the results of the in vitro test confirmed the
observation that both (±)-LSF enantiomers acted stronger as
hrPDE4B and hrPDE7A inhibitors compared to PTX. IC50
values of R-(-)-LSF and S-(+)-LSF versus PTX as hrPDE4B
inhibitors were about two times lower. Moreover, IC50 values
of PTX and (±)-LSF calculated using PK/PD model after con-
version to μM are of the same order of magnitude as IC50
values assessed for both compounds using hrPDE4B (main
cAMP hydrolysing enzyme) in the in vitro experiment and
were equal 16.09 and 12.23 μM for PTX and (±)-LSF, respec-
tively. Although enzymes used in the in vitro assay are human
recombinant proteins, it has been demonstrated that PDE4
inhibitors have very similar IC50 values in relation to human
and rat recombinant PDE4B (Bian et al. 2004). However, it
must be kept in mind that PDE4 activity in rat blood leuko-
cytes is higher in comparison to that in human cells, probably
as a result of approximately 25 times higher expression of
PDE4 in rat leukocytes. Anti-inflammatory potency of PTX
and R-(-)-LSF has been assessed earlier using TNF-α as a
marker of pharmacological response and different PK/PD
models (Wyska 2010a). The results of these studies indicated
the presence of dose-dependent relationship between PTX or
R-(-)-LSF exposure and inhibition of TNF-α production in
serum of LPS-treated mice. The value of TNF-α IC50 for
PTX estimated in that experiment was lower than that ob-
served for R-(-)-LSF, but the influence of S-(+)-LSF or (±)-
LSF on TNF-α levels was not investigated. In this study, we
evaluated the influence of PTX and (±)-LSF administration on
TNF-α plasma levels in endotoxemic rats. These compounds
at both doses caused a significant decrease (p < 0.05) in
TNF-α concentrations. It may be concluded that the elevated
levels of cAMP in rat plasma correspond with the decreased
TNF-α levels after administration of both investigated PDE
inhibitors simultaneously with LPS. Moreover, in this study,
the correlation between decimal logarithms of peak TNF-α
and cAMP plasma levels in endotoxemic rats was demonstrat-
ed, indicating the potential utility of cAMP as a marker of non-
selective PDE inhibitors’ effect in inflammatory diseases. This
observation is in line with the results of in vitro study where a
correlation has been found between the decimal logarithms of
cAMP accumulation potency (EC50) and IC50 of TNF-α sup-
pressive action for a series of non-selective PDE inhibitors
(Semmler et al. 1993). However, these observations are not
in agreement with the results of in vitro studies using immune
cells from patients suffering from Gram-negative bacterial
pneumonia, where the elevated intracellular levels of cAMP
observed in human leukocytes were not correlated with the
suppression of TNF-α levels (Matsumoto et al. 2011).
In conclusion, the results of this study indicated that both
non-selective PDE inhibitors, PTX and (±)-LSF, differ in phar-
macokinetic and pharmacodynamic characteristics. The
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proposed PK/PD additive interaction IDR model II accurately
described the concentration–effect relationship between PTX or
(±)-LSF concentrations and cAMPplasma levels. The proposed
PK/PDmodels may serve as a tool for assessing PDE inhibitory
activity of new non-selective PDE or PDE4-selective inhibitors
in vivo. Moreover, due to cAMP immune weakening potential,
they can be used in studies on new immunomodulatory drugs,
which mechanism of action is based on the elevation of cAMP
levels.
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